Segall Bryant & Hamill LLC Cuts Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Segall Bryant & Hamill LLC reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 353,103 shares of the biopharmaceutical company’s stock after selling 2,073 shares during the period. Segall Bryant & Hamill LLC’s holdings in Halozyme Therapeutics were worth $16,882,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in HALO. Vanguard Group Inc. boosted its holdings in shares of Halozyme Therapeutics by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock valued at $634,999,000 after acquiring an additional 386,618 shares during the last quarter. LPL Financial LLC lifted its position in Halozyme Therapeutics by 36.6% during the fourth quarter. LPL Financial LLC now owns 207,003 shares of the biopharmaceutical company’s stock valued at $9,897,000 after purchasing an additional 55,410 shares during the period. Samalin Investment Counsel LLC boosted its holdings in Halozyme Therapeutics by 8.8% in the fourth quarter. Samalin Investment Counsel LLC now owns 10,607 shares of the biopharmaceutical company’s stock worth $507,000 after purchasing an additional 860 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in Halozyme Therapeutics in the 4th quarter worth approximately $489,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Halozyme Therapeutics during the 4th quarter valued at $1,253,000. 97.79% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on HALO. Piper Sandler raised their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Wells Fargo & Company cut their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Benchmark reiterated a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. This represents a 11.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 31,697 shares of company stock worth $1,754,451. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Up 1.3 %

Shares of NASDAQ:HALO opened at $64.84 on Wednesday. The stock has a 50 day moving average of $58.39 and a 200 day moving average of $54.68. The company has a market cap of $8.01 billion, a PE ratio of 18.90, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $66.00. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.